Herantis Pharma

Alzheimer's disease drug
#Alzheimer's #FDA #Herantis Pharma #Parkinson's

Herantis to advance Alzheimer’s treatment after FDA meeting 

Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA).  The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to treat Alzheimer’s disease. … Read More

#News #Regulatory

Neuron firing
#Clinical trials #Herantis Pharma #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

First patients dosed in Phase Ib Parkinson’s disease trial

Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More

#News